| Name | SP-141 |
| Description | SP 141 is a MDM2 inhibitor.SP-141 promotes MDM2 auto-ubiquitination and degradation, with anticancer activity. |
| In vitro | SP141, which bound directly to MDM2, promoting its auto-ubiquitination and degradation by the proteasome.?The compound reduced levels of MDM2 in pancreatic cancer cell lines, as well as their proliferation, with 50% inhibitory concentrations <0.5 μM (0.38-0.50 μM).?Increasing concentrations of SP141 induced increasing levels of apoptosis and G2-M-phase arrest of pancreatic cancer cell lines, whether or not they expressed functional P53[1]. |
| In vivo | Injection of nude mice with SP141 (40 mg/kg/d) inhibited growth of xenograft tumors (by 75% compared with control mice), and led to regression of orthotopic tumors[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (3.08 mM), Sonication is recommended. DMSO : 4.4 mg/mL (13.56 mM), Sonication is recommended.
|
| Keywords | SP-141 | SP141 | pancreatic | MDM-2/p53 | Mdm2 | Inhibitor | inhibit | degradation | cancer | breast | auto-ubiquitination |
| Inhibitors Related | 10-Hydroxydecanoic Acid | Flubendazole | Diuron | Gallium maltolate | PRIMA-1 | XI-006 | Tebufenozide | D-(-)-3-Phosphoglyceric acid disodium | Thiabendazole | Triglycidyl isocyanurate | Methyl methanesulfonate | (E/Z)-10-Hydroxy-2-decenoic acid |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Ubiquitination Compound Library | Anti-Cancer Metabolism Compound Library | Pyroptosis Compound Library | Inhibitor Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |